The University of Wisconsin Carbone Cancer Center became one of the first six comprehensive cancer centers designated by the National Cancer Institute in 1973. UW Carbone is an integral part of the UW School of Medicine and Public Health and UW Health and brings together more than 330 physicians and scientists from 50 departments and nine schools across the University of Wisconsin-Madison campus to conduct research and translate laboratory discoveries into new patient treatments.
UW Carbone is a proud member of both the National Comprehensive Cancer Network and the Big Ten Cancer Research Consortium.
Clinical trials at UW Carbone are a collaborative process. We have more than 30 years of experience conducting clinical trials in Madison, at our partner community hospitals, and regional cancer centers across Wisconsin. More than 250 clinical trials are available at UW Carbone and through such programs as the Wisconsin Oncology Network, a regional network established to allow community health centers from throughout Wisconsin and northern Illinois to enroll patients in select cancer clinical trials that are open at UW Carbone.
UW Carbone’s scientific mission is organized around six scientific programs, which foster dynamic interactions, generation of ideas, and new applications for cancer treatment and prevention. Programs encompass laboratory research, clinical research, population sciences, and advanced research training:
Cancer Genetic and Epigenetic Mechanisms
Cancer Prevention and Control
Developmental Therapeutics
Human Cancer Virology
Imaging and Radiation Sciences
Tumor Microenvironment
Outreach – helping the public clearly understand cancer’s impact on our daily lives – is a key component of UW Carbone. Programs, partnerships, and affiliations include the following, which focus on research, community outreach, clinical trials, and work with underserved populations:
Cancer Health Disparities Initiative
Center for Tobacco Research and Intervention
Pain and Policy Studies Group
Rural Cancer Disparities Project
Spirit of EAGLES
Wisconsin Cancer Council
Wisconsin Comprehensive Cancer Control Program
Website: cancer.wisc.edu
A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers: Big Ten Cancer Research Consortium BTCRC-GI22-564
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409
A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
